FY26 trading update and strategic review of assets
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Healius Limited has announced a trading update for the fiscal year, including a strategic review of its assets, particularly Agilex Biolabs. The company expects underlying earnings before tax and depreciation to fall within a specified range. Pathology volumes and revenue have shown mixed results, with a slight decline in volumes but an increase in revenue for the year to date. Healius is exploring a potential sale of Agilex Biolabs following unsolicited approaches, which will not affect its core Pathology operations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Healius
- Healius announces 1H 2026 results
- Half Yearly Report and Accounts
- Half Year 2026 Results Presentation
- Healius wins contract for supply of services to ADF
- FY25 Results Presentation
Later from Healius
- Healius transitions pathology arrangements with Ramsay
- Webcast details for Healius FY26 Results
- Change of Share Registry Provider
- 2026 AGM - Notification of dates
- Notification of cessation of securities - HLS
Follow Healius into a list and get an email when it puts out news.
Follow Healius